[The effect of bemetizide-triamterene on the serum and whole body potassium in hypertensive patients (author's transl)].
The hypotensive effect of Bemetizide (B)/Triamterene (T) and its action on the potassium balance was investigated in 10 patients with renovascular hypertension. Within 14 days treatment with 50 mg B and 100 mg T a significant fall in the mean blood pressure of 174/106 to 143/95 mm Hg occurred. Whereas the serum potassium concentration fell by an average of 4.2 +/- 0.5 to 3.9 +/- 0.6 mEq/1 the whole body potassium showed only a slight insignificant regression by 50 and 80 mEq after 2--4 weeks; however, the potassium content related to the body weight remained unchanged. In contrast to monotherapy with chlorthalidone or hydrochlorothiazide, treatment with a combination of B and T caused no significant alteration of the intracellular content of potassium.
D000328:Adult; D000368:Aged; D001581:Benzothiadiazines; D004232:Diuretics; D004338:Drug Combinations; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006977:Hypertension, Renal / Q000188:drug therapy*; D007008:Hypokalemia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D011188:Potassium / Q000032:analysis; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use*; D014223:Triamterene / Q000627:therapeutic use*
D001581:Benzothiadiazines; D004232:Diuretics; D004338:Drug Combinations; D049993:Sodium Chloride Symporter Inhibitors; D011188:Potassium; D014223:Triamterene
Der Einfluss von Bemetizid/Triamteren auf das Serum- und Gesamtkörperkalium bei Hochdruckkranken.